Publications
Where expertise meets impact
Berry doesn’t just follow industry standards — we set them. Our team of award-winning statisticians, journal editors, and regulatory advisors leads the field in Bayesian and adaptive trial design. With research published in The New England Journal of Medicine, JAMA, and The Lancet, we’re driving innovation where it matters most.
Over 90% of our scientists published influential work this past year, advancing adaptive, Bayesian, and platform trial methodology. Our blend of academic rigor, regulatory insight, and real-world experience makes Berry a true authority in modern clinical trials.
Explore our most impactful peer-reviewed publications below.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Annals of Neurology
Neuroscience
Platform
Design and Statistical Innovations in a Platform Trial for Amyotrophic Lateral Sclerosis
June 22, 2023
2023
doi: 10.1002/ana.26714.
JAMA
Methodology
Other
Revisiting the Analogy Between Clinical Trials and Diagnostic Tests by Interpreting a Negative Trial as a Negative Test for Efficacy
June 20, 2023
2023
doi:10.1001/jama.2023.8972
Annals of Neurology
Neuroscience
Platform
Design and Statistical Innovations in a Platform Trial for Amyotrophic Lateral Sclerosis
May 28, 2023
2023
doi.org/10.1002/ana.26714
Project Euclid
Methodology
Allocation
Comment: Response Adaptive Randomization in Practice
May 1, 2023
2023
DOI: 10.1214/23-STS865F
Neurology Journals
Neuroscience
Platform
Results from the first four regimens of the HEALEY ALS Platform Trial (PL5.004)
April 28, 2023
2023
doi.org/10.1212/WNL.0000000000204032
Statistics in Medicine
Methodology
Platform
Allocation in platform trials to maintain comparability across time and eligibility
April 23, 2023
2023
https://doi.org/10.1002/sim.9750
JAMA
Infectious Disease
COVID-19
Platform
Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support–Free Days in Patients Hospitalized With COVID-19 A Randomized Clinical Trial
April 11, 2023
2023
doi: 10.1001/jama.2023.4480.
JAMA Network Open
Neuroscience
Alzheimer's Disease
Dose Ranging
Lecanemab for Patients With Early Alzheimer Disease Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical Trial
April 11, 2023
2023
doi:10.1001/jamanetworkopen.2023.7230
No results found.
There are no results with this criteria. Try changing your search.